Phasing Out Phase 3 What if drugs were released to the public earlier, then graded on their performance in the real world? Read the article here: http://protomag.com/articles/phasing-out-phase-3
Next Wave Forum
December 12–13, 2017 at MIT Biomedical science is outpacing the system. Barriers prevent patients’ access to innovations. Are you ready to innovation how we innovate? The Next Wave in Adaptive Biomedical … Read More
Mark Trusheim featured on Bloomberg News
BLOOMBERG: Novartis’s $475,000 Cancer Breakthrough Heralds New Era of Cures There are more than 600 gene and cell therapies in clinical trials today, according to Mark Trusheim, a strategic director … Read More
MIT NEWDIGS Hosts Design Lab on Efficacy to Effectiveness (E2E) data and decision-making
Industry leaders, patient advocates, regulators, policymakers collaborate to identify strategies for better data use in healthcare innovation CAMBRIDGE, MASSACHUSETTS—The MIT NEW Drug Development ParadIGmS (NEWDIGS) initiative, an international biomedical innovation … Read More
AI and machine learning key enablers of healthcare value, expert panel says
MIT NEWDIGS Director and advisor speak at LIGHT Forum on AI in Healthcare CAMBRIDGE, MASSACHUSETTS—MIT NEW Drug Development ParadIGmS (NEWDIGS) director Dr Gigi Hirsch, and program advisor R. John Glasspool … Read More
MIT NEWDIGS Hosts Design Lab on New Gene and Oncology Therapy Financing Models
Industry leaders, patient advocates, policymakers collaborate to lower barriers to potentially curative treatments CAMBRIDGE, MASSACHUSETTS—The MIT NEW Drug Development ParadIGmS (NEWDIGS) initiative, an international biomedical innovation “think and do tank” … Read More
Dr Gigi Hirsch and John Glasspool to speak at LIGHT Forum
MIT NEWDIGS director Dr Gigi Hirsch and her colleague R. John Glasspool will address the LIGHT Forum on the impact of artificial intelligence and Big Data on healthcare. They will … Read More
Hilary Malone joins MIT NEWDIGS Executive Committee
Regulatory and business leader will help accelerate system-wide biomedical innovation CAMBRIDGE, MASSACHUSETTS, 1 MARCH 2017—The MIT New Drug Development Paradigms Initiative (NEWDIGS) announced today that Hilary Malone, Chief Regulatory Officer … Read More
Adaptive Pathways create win-win scenarios for patients and pharma
QuintilesIMS, May 2017Jon Resnick In Europe, the concept of ‘adaptive pathways’ offers a faster route to critical medicines for patients with highest unmet needs through an iterative process of early … Read More
Enabling Precision Medicine: The Role of Genetics in Clinical Drug Development: Proceedings of a Workshop
Forum on Drug Discovery, Development, and Translation and the Roundtable on Genomics and Precision Health of the National Academies of Sciences, Engineering, and Medicine, March 8, 2017 Read the meeting … Read More